Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Curr Opin Oncol. 1998 Nov;10(6):542-7.

Tumor-specific adoptive T-cell therapy for CD40+ B-cell malignancies.

Author information

  • 1Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

Abstract

It is now widely accepted that current standard therapy does not lead to cure for the majority of patients with B-cell malignancies. In the search for novel treatment modalities and with the discovery of tumor-antigen--derived peptides recognized by T cells in the context of major histocompatibility complex class I and II molecules, active and passive immunotherapy has moved to center stage once again. Whereas most lymphoma research in this area has focused on vaccination strategies using the tumor-specific idiotype as a target antigen, this review focuses on the potential of a new strategy of adoptive transfer of antigen-specific T- for B-cell malignancies. Murine in vivo models and preclinical experiments suggest that we are now ready to enter the clinical arena to evaluate whether adoptive transfer of autologous or allogeneic antigen-specific T cells is a feasible and efficacious therapy approach for the treatment of B-cell malignancies. Potential obstacles to this strategy are also discussed.

PMID:
9818233
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk